Similarly, transfection of the prostate cancer cell line LNCaP with wild-type ALK5 restored the tumor suppressive effects of TGF-β, whereas loss of ALK5 activity has been linked with advanced disease stage and poor 4-year survival in patients with prostate cancer (112–114). Here, TGFBR1 is linked to prostate carcinoma.